减肥效果高出47% 礼来称替尔泊肽试验数据击败司美格鲁肽

澎湃新闻
04 Dec 2024

替尔泊肽“单挑”司美格鲁肽,全球两大减肥药王者的较量有了一项头对头数据。  当地时间12月4日,美国礼来公司(LLY.US)宣布,在72周时,其减重版替尔泊肽Zepbound的参与者减掉了50.3磅(22.8公斤),而使用诺和诺德减重版司美格鲁肽Wegovy的参与者减掉了33.1磅(15公斤)。与Wegovy相比,Zepbound的减肥效果高出47%。  礼来还提到,在72周时,在这项针对肥胖或...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10